Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 4.11    
    

        "CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS, WHICH ARE IDENTIFIED BY ***." 

 
 

LICENSE AGREEMENT    
    

        Effective as of February 5, 2004 ("EFFECTIVE DATE"), GENETIC TECHNOLOGIES LIMITED, having an office at 60
Hanover Street, Fitzroy, Victoria 3065, Australia ("GTG") and LABORATORY CORPORATION OF AMERICA HOLDINGS, a Delaware corporation having an office at 430
South Spring Street, Burlington, NC 27215, USA ("LICENSEE"), agree as follows: 

	ARTICLE I
 BACKGROUND
	

1.1	
 	

As a result of privately funded research over the course of many years, GTG now holds certain intellectual property rights in a variety of countries throughout the world relating to methods and processes used to extract gene discovery and diagnostic
utility from the non-coding region of genomes.
	

1.2	
 	

LICENSEE wishes to acquire licenses under and to obtain access to GTG's non-coding patents to the extent that they are required in accordance with applicable law in order to: 1) provide clinical laboratory diagnostic testing services and other
testing services offered by LICENSEE and/or SUBSIDIARIES of LICENSEE on humans in the United States, it territories, and Canada ("DIAGNOSTIC TESTING PURPOSE"); and 2) provide and conduct contract clinical trials and research protocols and
services in the United States, its territories, and Europe solely for (i) assisting third parties, including, but not limited to pharmaceutical companies; and (ii) internal purposes of LICENSEE and/or SUBSIDIARIES of LICENSEE in connection
with regulatory compliance ("CLINICAL TRIALS PURPOSE").
	

1.3	
 	

GTG is prepared to grant a non-exclusive license to LICENSEE under its non-coding patents, subject to the terms and conditions of this AGREEMENT.
	

ARTICLE II
 GENERAL DEFINITIONS AND RELATIONSHIPS AMONG DEFINITIONS
	

2.1	
 	

"AGREEMENT" means this document, its attachments, all addenda, schedules, exhibits, appendices, and any amendments to the foregoing.
	

2.2	
 	

"CLINICAL TRIALS LICENSED SERVICES" means research services and clinical trials performed by LICENSEE or a SUBSIDIARY of LICENSEE and that but for the license granted herein would infringe or contribute to the infringement of one or more claims of a
LICENSED PATENT.
	

2.3	
 	

"CONFIDENTIAL INFORMATION" means any and all information which is disclosed by either party to the other verbally, electronically, visually, or in a written or other tangible form which is either identified at the time of disclosure as confidential
or should be reasonably understood to be confidential or proprietary. CONFIDENTIAL INFORMATION includes, but is not limited to, the specific terms and/or conditions of this AGREEMENT, trade secrets, ideas, processes, formulas, programs, software,
source of supply, technology, discoveries, developments, inventions, techniques, marketing plans, strategies, forecasts, unpublished financial statements, prices, costs, and customer lists.
	 	 	 	 	 

 

	

2.4	
 	

"DIAGNOSTIC TESTING LICENSED SERVICES" means diagnostic service testing, or other testing service offered by LICENSEE and/or SUBSIDIARIES of LICENSEE (i) performed by LICENSEE or a SUBSIDIARY of LICENSEE; and (ii) that but for the license
granted herein would infringe or contribute to the infringement of one or more claims of a LICENSED PATENT.
	

2.5	
 	

"EXCLUDED FIELD" means genetic analysis using or based upon, in whole or in part, the genotyping of more than one hundred thousand (100,000) putative single nucleotide polymorphisms, such polymorphisms found in three (3) or more chromosomes of
the relevant organism.
	

2.6	
 	

"EXCLUSION TIME PERIOD" means the period from the EFFECTIVE DATE until August 31, 2006.
	

2.7	
 	

"FIELD OF USE" means, during the EXCLUSION TIME PERIOD, diagnostic service testing and other testing services offered by LICENSEE and/or SUBSIDIARIES of LICENSEE for humans and clinical trials and research, other than the EXCLUDED FIELD, and upon
expiration of the EXCLUSION TIME PERIOD means diagnostic service testing and other testing services offered by LICENSEE and/or SUBSIDIARIES of LICENSEE for humans and clinical trials and research without limitation.
	

2.8	
 	

GTG and LICENSEE may be commonly referred to as "parties" (in singular and plural usage, as required by the context).
	

2.9	
 	

"LICENSED PATENT(S)" means individually or collectively (i) the United States patents of GTG listed in the attached Exhibit A; (ii) all reissues, reexaminations, divisionals, continuations, continuations-in-part, substitutions, or
other applications claiming priority from such patents and any patents which may issue on such other applications, or extensions of such patents; and (iii) foreign counterparts of any of the foregoing.
	

2.10	
 	

"LICENSED SERVICES" means CLINICAL TRIALS LICENSED SERVICES and DIAGNOSTIC TESTING LICENSED SERVICES.
	

2.11	
 	

"QUARTERLY LICENSE ANNUITY" means a fee of (i) *** per quarter during the year 2004; (ii) *** per quarter during each year of the TERM from the year 2005 through the year 2010; and (iii) *** per quarter during each year of the TERM
from the year 2011 through the year 2015.
	

2.12	
 	

"SUBSIDIARY" means any corporation, company or other legal entity, in which more than fifty percent (50%) of the shares entitled to vote for the election of directors or persons performing similar functions are, now or hereafter, owned or controlled,
directly or indirectly by a party hereto, or jointly by the parties hereto; provided, however, that any corporation, company or other legal entity shall be a SUBSIDIARY only for as long as such ownership or control exists.
	

2.13	
 	

"TERRITORY" means Canada and the United States of America (including its territories).
	

2.14	
 	

"TERM" means from the EFFECTIVE DATE until there is no longer a VALID PATENT CLAIM (due to expiration or otherwise), except as otherwise provided in Article VII.
	

2.15	
 	

"VALID PATENT CLAIM" shall mean any claim in a filed and unabandoned patent application or unexpired patent with the LICENSED PATENTS, which claim has not been held unpatentable, unenforceable, or invalid by a decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been finally abandoned or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise.
	 	 	 	 	 

2

 

	

ARTICLE III
 RELEASE
	

3.1	
 	

Upon execution of this AGREEMENT by both parties and payment in full by LICENSEE of the PREPAYMENT (defined in Section 5.2) to GTG, GTG, and any person or entity claiming through GTG (including without limitation any affiliates, predecessors,
successors or assigns of GTG), hereby waive, release and forever discharge LICENSEE, all SUBSIDIARIES of LICENSEE, and their respective successors, assigns, directors, officers, employees and agents, both current and former (collectively, the
"RELEASED PARTIES") from any and all claims, suits, demands, actions, losses, costs, damages, expenses, liabilities and obligations whatsoever, whether known or unknown, arising from or relating to (a) any acts or omissions of the RELEASED
PARTIES on or before the EFFECTIVE DATE or December 31, 2003, whichever is later (the "RELEASE DATE"), (b) any events, occurrences, conditions or circumstances occurring on or before the RELEASE DATE, or (c) any transactions,
relationships, arrangements or other matters of any kind or nature existing at any time on or before the RELEASE DATE (collectively, the "RELEASED MATTERS"). This waiver and release includes, but is not limited to, any claims arising from or related
to the infringement or misappropriation, or alleged infringement or misappropriation, of any intellectual property or other proprietary rights of GTG (including without limitation the LICENSED PATENTS) by the RELEASED PARTIES.
	

3.2	
 	

GTG further agrees that it will not institute or participate in any legal action or administrative complaint against the RELEASED PARTIES arising out of or related to the RELEASED MATTERS. In the event of a breach of this Article 3 of this
AGREEMENT, the RELEASED PARTIES shall be entitled to recover from GTG attorneys' fees and expenses incurred by the RELEASED PARTIES defending such lawsuit filed by, on behalf of or otherwise involving GTG.
	

ARTICLE IV
 GRANT TO LICENSEE
	

4.1	
 	

Subject to the terms and conditions of this AGREEMENT, GTG hereby grants to LICENSEE, during the TERM of this AGREEMENT:
	

 	
 	

(i)	
 	

A non-exclusive, non-assignable, annual fee-bearing license under the LICENSED PATENTS (without the right to sublicense except to LICENSEE's SUBSIDIARIES) to perform, use, sell, and offer to sell DIAGNOSTIC TESTING LICENSED SERVICES in the FIELD OF
USE solely within the TERRITORY for the DIAGNOSTIC TESTING PURPOSE; and
	

 	
 	

(ii)	
 	

A non-exclusive, non-assignable, annual fee-bearing license under the LICENSED PATENTS (without right to sublicense except to LICENSEE's SUBSIDIARIES) to perform, use, sell, and offer to sell CLINICAL TRIALS LICENSED SERVICES in the FIELD OF USE in
the United States, its territories, and Europe (regardless of where the samples originate or where the sponsor may be located) for the CLINICAL TRIALS PURPOSE.
	

4.2	
 	

All rights not explicitly granted to LICENSEE are reserved by GTG. Not limiting the foregoing, LICENSEE acknowledges that it is not granted any rights to any other patents or other intellectual property rights of GTG or any third party.
	 	 	 	 	 

3

 

	

4.3	
 	

The rights and licenses granted by GTG in this AGREEMENT are personal to LICENSEE. Except as set forth in Section 4.4 and Section 11.6, LICENSEE shall not assign or otherwise transfer (by operation of law or otherwise) any license or right
granted hereunder or any interest therein, without the prior written consent of GTG (which may be withheld in GTG's sole and absolute discretion). Any attempted assignment or transfer without such prior written consent shall be void and shall upon
written notice by GTG terminate all rights of LICENSEE under this AGREEMENT.
	

4.4	
 	

LICENSEE may extend the license granted under this AGREEMENT to SUBSIDIARIES of LICENSEE provided that LICENSEE ensures that such SUBSIDIARIES are bound to the same terms and conditions of this AGREEMENT as is LICENSEE (except that such SUBSIDIARIES
shall not be obligated *** it being understood that payments by LICENSEE of the amounts under *** constitutes *** for LICENSEE and all SUBSIDIARIES of LICENSEE).
	

4.5	
 	

LICENSEE agrees that it will not intentionally and knowingly promote LICENSEE's reference testing to third party clinical laboratories for the purpose of circumventing the need for such third party clinical laboratories to license the LICENSED
PATENTS from GTG. In the event GTG believes LICENSEE is in breach of this Section 4.5, GTG shall notify LICENSEE of such breach in writing and the parties shall enter into good faith discussions to address such alleged breach promptly
thereafter. If the parties are unable to resolve the alleged breach by mutual agreement within thirty (30) days after LICENSEE's receipt of written notice of breach of this Section 4.5, then GTG may terminate this AGREEMENT upon ten
(10) days prior written notice to LICENSEE. Termination of this AGREEMENT shall be GTG's sole and exclusive remedy for any breach of this Section 4.5 by LICENSEE.
	

ARTICLE V
 CONSIDERATION
	

5.1	
 	

Subject to Section 5.2, LICENSEE agrees to pay to GTG the QUARTERLY LICENSE ANNUITY commencing on April 1, 2004 (such first payment constituting payment for the period from the EFFECTIVE DATE until March 31, 2004). Such QUARTERLY
LICENSE ANNUNITY payments are due and payable to GTG on January 1, April 1, July 1, and October 1 of each year of the TERM.
	

5.2	
 	

LICENSEE agrees to pay GTG *** upon execution of this AGREEMENT (the "PREPAYMENT"). The PREPAYMENT shall constitute a non-refundable credit against QUARTERLY LICENSE ANNUITY payments required under this AGREEMENT. Therefore, the PREPAYMENT shall be
deemed a prepayment of all QUARTERLY LICENSE ANNUITIES associated with the year 2004 ***, all QUARTERLY LICENSE ANNUITIES associated with the year 2005 ***, and *** of each of the four QUARTERLY LICENSE ANNUITIES associated with the year 2006. As
such, notwithstanding Sections 2.11 and 5.1, no further QUARTERLY LICENSE ANNUITIES will be payable by LICENSEE until the year 2006, and the remaining QUARTERLY LICENSE ANNUITIES to be paid by LICENSEE with respect to the year 2006 will be *** per
quarter.
	

5.3	
 	

All payments required under this AGREEMENT shall be sent by electronic wire transfer to:
	

 	
 	

 	
 	

Key Bank

#307070267

1130 Haxton Drive

Fort Collins, Colorado 80525

Account: Genetic Technologies Limited

Account Number: 76009 000 2576
	 	 	 	 	 

4

 

	

5.4	
 	

LICENSEE agrees to pay interest of five percent (5%) per year or the maximum rate allowed by law, whichever is less, on fees payable but not paid to GTG when due.
	

5.5	
 	

MATERIAL BREACH: A breach of any provision of this Article V or part thereof by LICENSEE shall be deemed a material breach.
	

ARTICLE VI
 WAIVER

        No
waiver by either party, express or implied, of any breach of any term, condition, or obligation of this AGREEMENT by the other party shall be construed as a waiver of any subsequent
breach of that term, condition, or obligation, or of any other term, condition, or obligation of this AGREEMENT of the same or different nature. 

	

ARTICLE VII
 TERM AND TERMINATION OF AGREEMENT
	

7.1	
 	

This AGREEMENT shall be in effect for the TERM, unless terminated earlier as provided herein.
	

7.2	
 	

Either party shall have the right to terminate this AGREEMENT upon any material breach of any term or condition of this AGREEMENT by the other party, which has not been corrected within thirty (30) days after receipt of a notice in writing with
reference to this Section 7.2 and such termination shall be without prejudice to any other rights or claims the aggrieved party may have against the other party. GTG shall have the right to terminate this AGREEMENT upon written notice in the
event that LICENSEE shall become involved in insolvency, dissolution, bankruptcy, or receivership proceedings affecting the operation of LICENSEE's business, or in the event that LICENSEE discontinues business for any reason.
	

7.3	
 	

LICENSEE shall have the right to terminate this AGREEMENT at any time by providing GTG with thirty (30) days written notice of such termination.
	

7.4	
 	

Termination or expiration of this AGREEMENT shall not affect any obligation owed by LICENSEE to GTG prior to the termination or expiration. Upon termination or expiration of this AGREEMENT:
	

 	
 	

7.4.1	
 	

all licenses granted hereunder shall immediately cease.
	

 	
 	

7.4.2	
 	

the parties shall promptly return all CONFIDENTIAL INFORMATION and copies thereof of the other party to the other party or certify in writing that they have destroyed all CONFIDENTIAL INFORMATION and copies thereof.
	

 	
 	

7.4.3	
 	

LICENSEE shall pay GTG the pro-rated amount of the quarterly payment set forth in Section 5.1 that had accumulated as of the date of termination or expiration for that year of the AGREEMENT.
	

7.5	
 	

SURVIVAL: Articles II, III, VIII and X shall survive the termination or expiration of this AGREEMENT.

5

  

	ARTICLE VIII
 CONFIDENTIALITY, PUBLICITY, PRESS RELEASES AND MARKING
	

8.1	
 	

LIMITATIONS ON USE AND DISCLOSURE: The parties agree that the terms and conditions set forth in this AGREEMENT are CONFIDENTIAL INFORMATION. The CONFIDENTIAL INFORMATION disclosed by either party ("DISCLOSING PARTY") to the other party ("RECEIVING
PARTY") constitutes the confidential and proprietary information of the DISCLOSING PARTY and the RECEIVING PARTY agrees to treat all CONFIDENTIAL INFORMATION of the other in the same manner as it treats its own similar proprietary information, but in
no case will the degree of care be less than reasonable care. The RECEIVING PARTY shall use CONFIDENTIAL INFORMATION of the DISCLOSING PARTY only in performing under this AGREEMENT and shall retain the CONFIDENTIAL INFORMATION in confidence and not
disclose to any third party (except as authorized under this AGREEMENT) without the DISCLOSING PARTY's express written consent. The RECEIVING PARTY shall disclose the DISCLOSING PARTY's CONFIDENTIAL INFORMATION only to those employees and contractors
of the RECEIVING PARTY who have a need to know such information for the purposes of this AGREEMENT, and such employees and contractors must have entered into agreements with the RECEIVING PARTY containing confidentiality provisions covering the
CONFIDENTIAL INFORMATION, or similar confidential information, with terms and conditions at least as restrictive as those set forth herein. Notwithstanding the foregoing, each party's confidentiality obligations hereunder shall not apply to
information which as evidenced by written records:
	

 	
 	

8.1.1	
 	

is already known to the RECEIVING PARTY, without an obligation of confidentiality, prior to disclosure by the DISCLOSING PARTY;
	

 	
 	

8.1.2	
 	

becomes publicly available without fault of the RECEIVING PARTY;
	

 	
 	

8.1.3	
 	

is rightfully obtained by the RECEIVING PARTY from a third party without restriction as to disclosure, or is approved for release by written authorization of the DISCLOSING PARTY; or
	

 	
 	

8.1.4	
 	

is developed independently by the RECEIVING PARTY without use of or access to the DISCLOSING PARTY's CONFIDENTIAL INFORMATION.
	

8.2	
 	

PERMITTED USE AND DISCLOSURE: Each party hereto is permitted to disclose this AGREEMENT and use or disclose the CONFIDENTIAL INFORMATION disclosed to it by the other party:
	

 	
 	

8.2.1	
 	

To the extent such use or disclosure is reasonably necessary in connection with complying with stock exchange rules; or
	

 	
 	

8.2.2	
 	

To its legal and/or financial advisors, provided such advisors maintain the confidentiality of this AGREEMENT; or
	

 	
 	

8.2.3	
 	

To the extent such use or disclosure is reasonably necessary in prosecuting or defending litigation, complying with applicable law, governmental regulation or court order, submitting information to tax or other governmental authorities, or otherwise
exercising its rights hereunder; or
	

 	
 	

8.2.4	
 	

To the extent necessary to enforce its rights under this AGREEMENT in connection with a legal proceeding or as required to be disclosed by law or governmental regulation.
	 	 	 	 	 

6

 

	

 	
 	

8.2.5	
 	

In the instances set forth in this Sections 8.2.3 or 8.2.4, the RECEIVING PARTY shall provide reasonable advance written notice to DISCLOSING PARTY of such disclosure and reasonably cooperate with the DISCLOSING PARTY in limiting such
disclosure.
	

8.3	
 	

PUBLICITY AND PRESS RELEASES: Neither party shall issue any press releases relating to this AGREEMENT without prior written approval of the other party; provided however, that:
	

 	
 	

8.3.1	
 	

Each party shall be permitted to post a copy of or provide a link on its web site to any permitted disclosures made under this AGREEMENT;
	

 	
 	

8.3.2	
 	

Each party may disclose the existence of the AGREEMENT only to the extent required to comply with any applicable law or regulation; and
	

 	
 	

8.3.3	
 	

LICENSEE shall be able to disclose to SUBSIDIARIES of LICENSEE the existence of this AGREEMENT and the terms of this AGREEMENT, provided such SUBSIDIARIES maintain the confidentiality of this AGREEMENT.
	

ARTICLE IX
 NOTICE
	

9.1	
 	

Any notice, request or statement hereunder shall be deemed to be sufficiently given or rendered when personally delivered, delivered by a major commercial rapid delivery courier service or mailed by certified or registered mail, return receipt
requested, and if given or rendered to LICENSEE, addressed to:
	

 	
 	

 	
 	

Laboratory Corporation of America Holdings

Attn: General Counsel

430 South Spring Street

Burlington, NC 27215

USA
	

 	
 	

or, if given or rendered to GTG, addressed to:
	

 	
 	

 	
 	

Dr. Mervyn Jacobson

Executive Chairman

Genetic Technologies Limited

60 Hanover Street

Fitzroy, Victoria 3065

Australia
	

 	
 	

with a copy to:
	

 	
 	

 	
 	

Michael A. DeSanctis, Esq.

Faegre & Benson LLP

3200 Wells Fargo Center

1700 Lincoln Street

Denver, CO 80203

USA
	

 	
 	

or, in any case, to such changed address or person as GTG or LICENSEE shall have specified to the other by written notice.
	 	 	 	 	 

7

 

	

ARTICLE X
 REPRESENTATIONS AND WARRANTIES
	

10.1	
 	

GTG represents and warrants that it has the full right, power, and authority to enter into and perform its obligations under this AGREEMENT and grant to LICENSEE the license and other rights as set forth herein, and there are no outstanding
agreements, grants, licenses, encumbrances, liens, or agreements, either written or implied, inconsistent therewith or pursuant to which this AGREEMENT or the parties' performance hereunder would violate, breach, or cause a default. GTG further
represents and warrants that the LICENSED PATENTS are the only patents owned or controlled by GTG that LICENSEE needs to practice the methods disclosed in the patents listed in Exhibit A.
	

10.2	
 	

The execution, delivery, and performance of this AGREEMENT have been duly authorized by all necessary corporate actions on the part of GTG.
	

10.3	
 	

GTG covenants that GTG will not, nor will it offer to, sell, license, assign or otherwise transfer or encumber its patent rights and interests in and to (i) the United States patents 5,447,842 and 5,153,117; (ii) any patent applications
claiming priority from such patents; and (iii) foreign counterparts of such patents for a period of ninety (90) days from LICENSEE's receipt of that certain packet of confidential information related to GTG's fetal cell technology that is
the subject matter of that certain non-disclosure agreement effective as of September 5, 2003 by and between GTG and LICENSEE ("FETAL CELL INFORMATION"). GTG must deliver the FETAL CELL INFORMATION to LICENSEE on or before May 1,
2004.
	

10.4	
 	

LICENSEE represents and warrants that it has the full right, power, and authority to enter into and perform its obligations under this AGREEMENT, and there are no outstanding agreements, grants, licenses, encumbrances, liens, or agreements, either
written or implied, inconsistent therewith or pursuant to which this AGREEMENT or the parties' performance hereunder would violate, breach, or cause a default.
	

10.5	
 	

LICENSEE represents and warrants that the execution, delivery, and performance of this AGREEMENT have been duly authorized by all necessary corporate actions on the part of LICENSEE.
	

10.6	
 	

INDEMNIFICATION:
	

 	
 	

10.6.1	
 	

BY LICENSEE: LICENSEE shall indemnify, hold harmless, and defend GTG, and GTG's SUBSIDIARIES, affiliates, officers, directors, representatives, employees, or agents against any and all third party claims, causes of action, demands, judgments,
settlements, expenses, or losses including, but not limited to, reasonable attorneys' fees and court costs arising out of or in connection with: (i) any breach by LICENSEE of any representation, warranty, or covenant hereunder; (ii) the
failure of LICENSEE to perform any covenants or obligations contained in this AGREEMENT; or (iii) LICENSEE's negligent, reckless, or willful misconduct.
	

 	
 	

10.6.2	
 	

BY GTG: GTG shall indemnify, hold harmless, and defend LICENSEE, and LICENSEE's SUBSIDIARIES, affiliates, officers, directors, representatives, employees, or agents against any and all third party claims, causes of action, demands, judgments,
settlements, expenses, or losses including, but not limited to, reasonable attorneys' fees and court costs arising out of or in connection with: (i) any breach by GTG of any representation, warranty, or covenant hereunder; (ii) the failure
of GTG to perform any covenants or obligations contained in this AGREEMENT; or (iii) GTG's negligent, reckless, or willful misconduct.
	

 	
 	

10.6.3	
 	

The indemnifying party's indemnification obligations under this Section 10.6 are conditioned upon the indemnified party (a) giving prompt notice of the claim to the indemnifying party; (b) granting sole control of the defense or
settlement of the claim or action to the indemnifying party; and (c) providing reasonable cooperation to the indemnifying party and, at the indemnifying party's request and expense, assistance in the defense or settlement of the
claim.
	 	 	 	 	 

8

 

	

10.7	
 	

DISCLAIMER OF WARRANTIES: EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS, TO THE EXTENT ALLOWED BY APPLICABLE LAW, ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, RELATING TO THE LICENSED PATENTS AND THE LICENSED
SERVICES, INCLUDING WITHOUT LIMITATION THE WARRANTIES OF DESIGN, TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE (EVEN IF INFORMED OF SUCH PURPOSE), NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A
COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN ALL CASES WITH RESPECT THERETO.
	

10.8	
 	

LIMITATION OF LIABILITY: TO THE GREATEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, EXCEPT FOR A BREACH OF A PARTY'S OBLIGATIONS PURSUANT TO ARTICLE VIII, WITH RESPECT TO ANY CAUSE OF ACTION RELATING TO OR ARISING FROM THIS AGREEMENT (WHETHER UNDER
THIS ARTICLE X OR OTHERWISE): (I) NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER, AND (II)
 NEITHER PARTY SHALL BE LIABLE FOR ANY AMOUNTS IN EXCESS OF THE TOTAL AMOUNTS PAID TO GTG BY LICENSEE HEREUNDER DURING THE 12 MONTHS IMMEDIATELY PRECEDING THE EVENT GIVING RISE TO SUCH LIABILITY.
	

10.9	
 	

Nothing contained in this AGREEMENT shall be construed as:
	

 	
 	

10.9.1	
 	

a warranty or representation by GTG as to the validity or scope of any LICENSED PATENT except as provided expressly herein;
	

 	
 	

10.9.2	
 	

a warranty or representation that any use or performance contemplated herein will be free from infringement of patents other than those LICENSED PATENTS under which and to the extent to which licenses are in force hereunder;
	

 	
 	

10.9.3	
 	

an agreement to bring or prosecute actions or suits against third parties for infringement or conferring any right to bring or prosecute actions or suits against third parties for infringement;
	

 	
 	

10.9.4	
 	

conferring any right to use by either party, in advertising, publicity, or otherwise, any trademark, trade name or name, or any contraction, abbreviation or simulation thereof, of the other party;
	

 	
 	

10.9.5	
 	

conferring by implication, estoppel or otherwise, upon LICENSEE, any license or other right under any intellectual property or patent, except that expressly granted hereunder.
	

ARTICLE XI
 MISCELLANEOUS
	

11.1	
 	

SERVICE LITERATURE: To the extent practicable and consistent with LICENSEE's customary practices, LICENSEE will prominently display on any literature or other materials (in paper, electronic or other format) distributed with or about any LICENSED
SERVICES, as determined in LICENSEE's sole discretion, a notice indicating that any such LICENSED SERVICES are provided pursuant to a license from GTG under the LICENSED PATENTS, which patents are owned by GTG.
	 	 	 	 	 

9

 

	

11.2	
 	

CONSTRUCTION: This AGREEMENT has been negotiated by the parties and their respective counsel. This AGREEMENT shall be interpreted fairly in accordance with its terms and without any strict construction in favor of or against either party. This
AGREEMENT shall not be construed in favor or against either party by reason of the authorship of any provisions hereof. The existence or absence of any term or condition of this AGREEMENT shall not be used in the construction or interpretation of any
other agreement between the parties.
	

11.3	
 	

MARKINGS: To the extent practicable and consistent with LICENSEE's customary practices, LICENSEE shall use markings as GTG may reasonably request from time to time, including, but not limited to, marking the LICENSED SERVICES and/or documentation
related thereto with patent number(s) as determined in LICENSEE's sole discretion.
	

11.4	
 	

MODIFICATION: This AGREEMENT sets forth the entire agreement and understanding between the parties as to the subject matter of this AGREEMENT and merges all prior discussions between the parties, and no one of the parties shall be bound by any
modification of this AGREEMENT, or by any conditions, definitions, warranties, or representations with respect to the subject matter of this AGREEMENT, other than as expressly provided for herein, or as duly set forth on or subsequent to the
EFFECTIVE DATE in writing and signed by duly authorized representatives of the party to be bound thereby.
	

11.5	
 	

CHOICE OF LAW: This AGREEMENT and matters connected with the performance thereof shall be construed, interpreted, applied and governed in all respects in accordance with the laws of the State of Delaware (excluding conflicts of laws).
	

11.6	
 	

ASSIGNMENT. Neither party may assign this AGREEMENT without the prior written consent of the other party except in the event of the sale of all or substantially all of a party's capital stock, business or assets whether by merger or otherwise
pertaining to the subject matter of this AGREEMENT, such party may assign this AGREEMENT to its successor and shall provide notice of such assignment to the other party; provided however, that prior to any assignment permitted herein by LICENSEE,
LICENSEE's successor must expressly assume in writing LICENSEE's obligations under this AGREEMENT and expressly acknowledge in writing that products and services of such successor existing prior to such assignment shall not be LICENSED
SERVICES.
	

11.7	
 	

ATTORNEYS' FEES: Upon resolution of any claim or controversy arising under this AGREEMENT, the prevailing party shall be awarded its reasonable attorneys' fees and costs in addition to any other amount awarded.
	

11.8	
 	

EQUITABLE REMEDIES: Each party acknowledges that its breach of any of its obligations set forth in Article VIII could result in immediate and irreparable damage to the other party and that no adequate remedy may exist at law. Each party
acknowledges and agrees that the other party may seek any available remedy, whether in law or equity, upon the other party's breach of any of its obligations set forth in Article VIII.
	

11.9	
 	

INDEPENDENT BUSINESS: The parties acknowledge that their business operations are completely independent and nether party shall at any time hold itself out as an agent or representative of the other party. No partnership, joint venture, or other
relationship shall be deemed to exist by virtue of this AGREEMENT.
	

11.10	
 	

INDEPENDENT TERMS: All the terms of this AGREEMENT shall be independent and unconditional so that the performance of any one term shall not be subject to any set off or counterclaim.
	

11.11	
 	

SEVERABILITY: In the event any clause or term of this AGREEMENT is determined to be void, invalid, or unenforceable, the clause shall be reformed to the extent necessary in order to overcome the limitation and give effect to the original intent of
the parties and economic effect of the original provision and, as revised this AGREEMENT shall remain in full force and effect.
	 	 	 	 	 

10

 

	

11.12	
 	

HEADINGS: The headings contained within this AGREEMENT are for convenience and reference purposes only. They do not form a part hereof and shall not affect the meaning or interpretation of this AGREEMENT.
	

11.13	
 	

FURTHER ASSURANCES: The parties hereto shall execute such further documents and perform such further acts as may be necessary to comply with the terms of this AGREEMENT and consummate the transactions herein provided.
	

11.14	
 	

FORCE MAJEURE: Neither party shall be held responsible if the fulfillment of any terms or provisions of this AGREEMENT are delayed or prevented by wars, revolutions, fires, floods, acts of God, acts of terrorism whether actual or threatened, or other
causes similar to those enumerated and not within the control of the party whose performance is interfered with, and which by the exercise of reasonable diligence, the party is unable to prevent.
	

11.15	
 	

COUNTERPARTS: This AGREEMENT may be executed in counterparts (and evidenced by facsimile signatures), each of which will be deemed an original and all of which together constitute one instrument.

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK] 

11

 

        IN
WITNESS WHEREOF, the parties hereto have caused their authorized representatives to execute this AGREEMENT. 

	GTG:	 	LICENSEE:
	

GENETIC TECHNOLOGIES LIMITED	
 	

LABORATORY CORPORATION OF AMERICA HOLDINGS
	

By:	
 	

	
 	

By:	
 	

	

 Printed Name/Date	
 	

 Printed Name/Date
	

 Title	
 	

 Title

12

 
 
 

EXHIBIT A
  LICENSED PATENTS    
    

United
States Patent No. 5,192,659

United States Patent No. 5,612,179

United States Patent No. 5,789,568

United States Patent No. 5,851,762

United States Patent No. 5,096,557 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK] 

13

QuickLinks

Exhibit 4.11

LICENSE AGREEMENT

EXHIBIT A LICENSED PATENTSQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 4.15    
    

"CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS, WHICH ARE IDENTIFIED BY ***." 

 
 

LICENSE AGREEMENT    
    

        Effective as of September 17, 2004 ("EFFECTIVE DATE"), Genetic Technologies Limited, having an office at 60
Hanover Street, Fitzroy, Victoria 3065, Australia ("GTG") and Genzyme Corporation, having an office at 500 Kendall Street, Cambridge, MA, 02142, USA
("LICENSEE"), agree as follows: 

	ARTICLE I
 BACKGROUND
	

1.1	
 	

GTG represents that it has certain proprietary and intellectual property rights pertaining to methods and processes used to extract gene discovery and diagnostic utility from the non-coding region of genomes.
	

1.2	
 	

LICENSEE wishes to acquire a license under, and to obtain access to GTG's non-coding patents in order to perform preclinical and human research and human genetic testing.
	

1.3	
 	

GTG is prepared to grant a non-exclusive license to LICENSEE under its non-coding patents, subject to the terms and conditions of this AGREEMENT.
	

ARTICLE II
 GENERAL DEFINITIONS AND RELATIONSHIPS AMONG DEFINITIONS
	

2.1	
 	

"AGREEMENT" means this document, its attachments, all addenda, schedules, exhibits, appendices, and any amendments to the foregoing.
	

2.2	
 	

"CONFIDENTIAL INFORMATION" means any and all information which is disclosed by either party to the other verbally, electronically, visually, or in a written or other tangible form which is either identified or should be reasonably understood to be
confidential or proprietary. CONFIDENTIAL INFORMATION includes, but is not limited to, the specific terms and/or conditions of this AGREEMENT, trade secrets, ideas, processes, formulas, programs, software, source of supply, technology, discoveries,
developments, inventions, techniques, marketing plans, strategies, forecasts, unpublished financial statements, prices, costs, and customer lists.
	

2.3	
 	

"EXCLUDED FIELD" means genetic analysis using or based upon, in whole or in part, the genotyping of more than one hundred thousand (100,000) putative single nucleotide polymorphisms, such polymorphisms found in three (3) or more chromosomes of
the relevant organism.
	

2.4	
 	

"EXCLUSION TIME PERIOD" means the period from the EFFECTIVE DATE until August 31, 2006.
	

2.5	
 	

"FIELD OF USE" means, during the EXCLUSION TIME PERIOD, preclinical and human research and human genetic testing other than the EXCLUDED FIELD, and upon expiration of the EXCLUSION TIME PERIOD means preclinical and human research and human genetic
testing.
	

2.6	
 	

GTG and LICENSEE are hereunder commonly referred to as "parties" (in singular and plural usage, as required by the context).
	

2.7	
 	

"LICENSE ANNUITY FEE" means a fee of one million Australian Dollars (AUD $1,000,000.00) incurred on each anniversary of the EFFECTIVE DATE for the TERM.
	 	 	 	 	 

 

	

2.8	
 	

"LICENSED PATENT(S)" means the patents listed in Appendix "A" attached to this AGREEMENT and all reissues, reexaminations, divisionals, continuations, continuations-in-part, substitutions, and extensions of the foregoing, applications therefor, and
patents which may issue upon such applications.
	

2.9	
 	

"LICENSED PRODUCT(S)" means services performed by LICENSEE or a SUBSIDIARY of LICENSEE that but for the license granted herein would infringe or contribute to the infringement of one or more valid claims of a LICENSED PATENT.
	

2.10	
 	

"SUBSIDIARY" means any corporation, company or other legal entity, in which more than fifty percent (50%) of the shares entitled to vote for the election of directors or persons performing similar functions are, now or hereafter, owned or controlled,
directly or indirectly by a party hereto, or jointly by the parties hereto; provided, however, that any corporation, company or other legal entity shall be a SUBSIDIARY only for as long as such ownership or control exists.
	

2.11	
 	

"TERM" means the lives of the LICENSED PATENTS, except as otherwise provided in Article VII.
	

2.12	
 	

"TERRITORY" means worldwide, excluding Australia, New Zealand, Singapore and Hong Kong.
	

Article III
 RELEASE
	

3.1	
 	

Subject to the licenses set forth herein, GTG agrees that, providing LICENSEE fully and faithfully discharges all obligations undertaken by LICENSEE in this AGREEMENT, including, but not limited to, the confidentiality obligations, the obligations
set forth in Section 5.1 and the obligation to pay the LICENSE ANNUITY FEE payments during the TERM and, provided further, that this AGREEMENT is not terminated for LICENSEE's material breach of any term or condition hereof, GTG hereby releases
and discharges LICENSEE, its officers, directors, employees and agents, from all claims, demands, and rights of action which GTG may have as of the EFFECTIVE DATE on account of infringement of any LICENSED PATENT prior to the EFFECTIVE DATE to the
extent the acts constituting such infringement are covered by the license granted hereunder. Failure of LICENSEE at any time to so discharge its obligations hereunder shall constitute a waiver of the benefits of this Section 3.1 and shall
forthwith restore to GTG its full rights as they existed on the EFFECTIVE DATE; provided, however, that upon termination of this AGREEMENT by LICENSEE pursuant to Article VII at any time after
LICENSEE satisfies Section 5.1 hereof, this Section 3.1 shall survive as to any liability incurred by LICENSEE prior to the date of such termination.
	

Article IV
 GRANT TO LICENSEE
	

4.1	
 	

Subject to the terms and conditions of this AGREEMENT, GTG hereby grants and agrees to grant to LICENSEE and LICENSEE's SUBSIDIARIES, during the TERM of this AGREEMENT, a nonexclusive, non-assignable (except as provided in Section 4.2),
non-transferable, annual fee-bearing, license under the LICENSED PATENTS (without the right to sublicense) to make, use, sell, offer for sale, and import LICENSED PRODUCTS in the FIELD OF USE throughout the TERRITORY.
	 	 	 	 	 

2

 

	

4.2	
 	

The rights and licenses granted by GTG in this AGREEMENT are personal to LICENSEE and LICENSEE's SUBSIDIARIES. LICENSEE and LICENSEE's SUBSIDIARIES shall not assign or otherwise transfer any license or right granted hereunder or any interest therein
without the prior written consent of GTG (which may be withheld in GTG's sole and absolute discretion), except to a purchaser of all or substantially all of the business of LICENSEE to which this AGREEMENT relates, whether by merger, sale of stock,
sale of assets or otherwise; provided, however that prior to the transfer of ownership such purchaser must expressly assume in writing LICENSEE's obligations under this AGREEMENT and expressly acknowledge in writing that services of such purchaser
performed prior to the transfer of ownership shall not be considered LICENSED PRODUCTS.
	

4.3	
 	

All rights not explicitly granted to LICENSEE and LICENSEE's SUBSIDIARIES are reserved by GTG. Not limiting the foregoing, LICENSEE acknowledges that it is not granted any rights to any other patents or other intellectual property rights of GTG or
any third party other than the LICENSED PATENTS.
	

4.4	
 	

LICENSEE shall be responsible for all acts and omissions of LICENSEE's SUBSIDIARIES related to the rights granted to LICENSEE's SUBSIDIARIES under this AGREEMENT and LICENSEE shall ensure that LICENSEE's SUBSIDIARIES are in compliance with the terms
and conditions of this AGREEMENT at all times.
	

Article V
 CONSIDERATION
	

5.1	
 	

As partial consideration for the release of Article III and the licenses granted by this AGREEMENT, LICENSEE agrees to pay to GTG a non-refundable license issue fee of seven million two hundred fifty thousand Australian Dollars (AUD
$7,250,000.00) in the following form:
	

 	
 	

5.1.1	
 	

a cash component of five million Australian Dollars (AUD $5,000,000.00) within thirty (30) days after the EFFECTIVE DATE; and
	 	 	 	 	 

3

 

	

 	
 	

5.1.2	
 	

an in-kind component allocated a value of two million two hundred fifty thousand Australian Dollars (AUD $2,250,000.00) and consisting of a license agreement, with the right to sublicense in accordance with the terms of LICENSEE's license agreement
with Johns Hopkins University, (the "*** LICENSE") to be negotiated in good faith between GTG and LICENSEE and executed within a reasonable time from the EFFECTIVE DATE under patents owned by Johns Hopkins University relating to the *** and licensed
by LICENSEE (the "*** PATENTS"). If LICENSEE and GTG do not execute the *** LICENSE within a reasonable time after the EFFECTIVE DATE, then (i) the parties shall negotiate in good faith and agree upon substitute consideration for the *** LICENSE
and (ii) the parties' failure to execute the *** LICENSE shall not be a breach of this Section 5.1.2. The *** LICENSE shall be non-exclusive, provided, however, that any license to the ***
PATENTS granted by LICENSEE to any third party after the EFFECTIVE DATE shall not include the right to sublicense. The *** LICENSE shall expire upon expiration of the *** PATENTS. The parties acknowledge and agree that the *** LICENSE shall contain
provisions for sharing net license signing fees, net royalties and any other consideration resulting from GTG's sublicensing efforts in connection with the *** PATENTS (the "SUBLICENSE REVENUE"). After deducting any and all amounts owed by LICENSEE
to Johns Hopkins University *** of such SUBLICENSE REVENUE shall be retained by GTG and *** of such SUBLICENSE REVENUE shall be paid to LICENSEE. The *** LICENSE shall include a mutually agreed upon mechanism for GTG to inform LICENSEE of its
discussions with potential sublicensees of the *** PATENTS. The *** LICENSE shall also provide that GTG shall not have the right to enforce or threaten to enforce the *** PATENTS, but shall provide a mechanism for enforcement as mutually agreed by
the parties. In no event shall LICENSEE be obligated to enforce the *** PATENTS.
	

5.2	
 	

As additional consideration for the rights and licenses granted by this AGREEMENT, LICENSEE agrees to pay to GTG the LICENSE ANNUITY FEE payments representing an annual fee in lieu of royalties. Such LICENSE ANNUITY FEE payments are due and payable
to GTG within fifteen (15) days of the anniversary of the EFFECTIVE DATE each year for the TERM. No other sums or royalties shall be due GTG, its successors, assigns and/or legal representatives as a result of this AGREEMENT or the license
hereunder.
	

5.3	
 	

All payments by LICENSEE to GTG shall be sent by electronic wire transfer to:
	

 	
 	

 	
 	
St. George Bank

333 Collins Street, Melbourne

Victoria, Australia

Bank State Branch Number: 333.030

Account: Genetic Technologies Limited

Account Number: 700390978
	

5.4	
 	

All fees payable hereunder by LICENSEE shall be made in Australian Dollars (AUD) and are payable to GTG's successors, heirs, or assigns, as appropriate.
	

5.5	
 	

LICENSEE agrees to pay interest of *** per year or the maximum rate allowed by law, whichever is less, on payments owed but not paid to GTG within thirty (30) days of such payment becoming due.
	

5.6	
 	

MATERIAL BREACH: Breach of any provision of this Article V or part thereof shall be deemed a material breach, except as set forth in Section 5.1.2(ii) hereof.
	 	 	 	 	 

4

 

	

ARTICLE VI
 WAIVER
	

6.1	
 	

No waiver by either party, express or implied, of any breach of any term, condition, or obligation of this AGREEMENT by the other party shall be construed as a waiver of any subsequent breach of that term, condition, or obligation, or of any other
term, condition, or obligation of this AGREEMENT of the same or different nature.
	

ARTICLE VII
 TERM AND TERMINATION OF AGREEMENT
	

7.1	
 	

This AGREEMENT shall extend from the EFFECTIVE DATE hereof for the TERM, unless terminated earlier as provided below.
	

7.2	
 	

Either party shall have the right to terminate this AGREEMENT upon any material breach of any term or condition of this AGREEMENT by the other party, which has not been corrected within thirty (30) days after receipt of a notice in writing with
reference to this Section 7.2 and such termination shall be without prejudice to any other rights or claims the aggrieved party may have against the other party. Termination shall not affect any obligation owed by LICENSEE to GTG prior to the
termination. GTG shall have the right to terminate this AGREEMENT in the event that LICENSEE shall become involved in insolvency, dissolution, bankruptcy, or receivership proceedings affecting the operation of its business, or in the event that
LICENSEE discontinues its business to which this AGREEMENT relates for any reason. In the event of termination of this AGREEMENT all rights granted to LICENSEE hereunder shall revert to GTG.
	

7.3	
 	

LICENSEE shall have the right to terminate this AGREEMENT for any reason upon thirty (30) days prior written notice to GTG.
	

7.4	
 	

SURVIVAL: Articles II, VIII, X, XI, Section 3.1 (as to any liability incurred by LICENSEE prior to the date of termination), this Section 7.4 and all payment obligations incurred prior to termination shall survive the termination of this
AGREEMENT.
	

Article VIII
 CONFIDENTIALITY, PUBLICITY AND PRESS RELEASES
	

8.1	
 	

LIMITATIONS ON USE AND DISCLOSURE: The parties agree that the terms and conditions set forth in this AGREEMENT are CONFIDENTIAL INFORMATION. The CONFIDENTIAL INFORMATION disclosed by either party ("DISCLOSING PARTY") to the other party ("RECEIVING
PARTY") constitutes the confidential and proprietary information of the DISCLOSING PARTY and the RECEIVING PARTY agrees to treat all CONFIDENTIAL INFORMATION of the other in the same manner as it treats its own similar proprietary information, but in
no case will the degree of care be less than reasonable care. The RECEIVING PARTY shall use CONFIDENTIAL INFORMATION of the DISCLOSING PARTY only in performing under this AGREEMENT and shall retain the CONFIDENTIAL INFORMATION in confidence and not
disclose to any third party (except as authorized under this AGREEMENT) without the DISCLOSING PARTY's express written consent. The RECEIVING PARTY shall disclose the DISCLOSING PARTY's CONFIDENTIAL INFORMATION only to those employees and contractors
of the RECEIVING PARTY who have a need to know such information for the purposes of this AGREEMENT, and such employees and contractors must have entered into agreements with the RECEIVING PARTY containing confidentiality provisions covering the
CONFIDENTIAL INFORMATION, with terms and conditions at least as restrictive as those set forth herein. Notwithstanding the foregoing, each party's confidentiality obligations hereunder shall not apply to information which as evidenced by written
records:
	 	 	 	 	 

5

 

	

 	
 	

8.1.1	
 	

is already known to the RECEIVING PARTY without an obligation of confidentiality prior to disclosure by the DISCLOSING PARTY;
	

 	
 	

8.1.2	
 	

is or becomes publicly available without fault of the RECEIVING PARTY;
	

 	
 	

8.1.3	
 	

is rightfully obtained by the RECEIVING PARTY from a third party without restriction as to disclosure, or is approved for release by written authorization of the DISCLOSING PARTY;
	

 	
 	

8.1.4	
 	

is developed independently by the RECEIVING PARTY without use of or access to the DISCLOSING PARTY's CONFIDENTIAL INFORMATION.
	

8.2	
 	

PERMITTED USE AND DISCLOSURE: Each party hereto is permitted to disclose this AGREEMENT and use or disclose the CONFIDENTIAL INFORMATION disclosed to it by the other party:
	

 	
 	

8.2.1	
 	

To the extent such use or disclosure is reasonably necessary in connection with complying with stock exchange rules.
	

 	
 	

8.2.2	
 	

To its legal and/or financial advisors, provided such advisors maintain the confidentiality of this AGREEMENT.
	

 	
 	

8.2.3	
 	

To the extent such use or disclosure is reasonably necessary to enforce its rights under this AGREEMENT in connection with a legal proceeding against the other party or as required to be disclosed by law or governmental regulation.
	

 	
 	

8.2.4	
 	

To the extent such use or disclosure is reasonably necessary in connection with prosecuting or defending litigation against the other party, complying with applicable law, court order, submitting information to tax or other governmental
authorities.
	

 	
 	

8.2.5	
 	

In the instances set forth in Sections 8.2.3 or 8.2.4, the RECEIVING PARTY shall provide reasonable advance written notice to DISCLOSING PARTY of such disclosure and reasonably cooperate with the DISCLOSING PARTY in limiting such
disclosure.
	

8.3	
 	

PUBLICITY AND PRESS RELEASES: GTG may issue one or more appropriate media/press releases with regard to the existence of this AGREEMENT with LICENSEE's prior review and approval; provided, however, that
such press releases shall not contain any financial terms of this AGREEMENT. Neither party shall issue any other press releases relating to this AGREEMENT without prior written approval of the other party; provided however, that:
	

 	
 	

8.3.1	
 	

Each party shall be permitted to post a copy of or provide a link on its web site to any press release issued pursuant to this Section 8.3 relating to this AGREEMENT;
	

 	
 	

8.3.2	
 	

GTG shall be able to disclose to other licensees and/or prospective licensees the identity of LICENSEE and the existence of this AGREEMENT (not including any terms); and
	

 	
 	

8.3.3	
 	

LICENSEE shall be able to disclose to customers and/or prospective customers, and Johns Hopkins University, the identity of GTG and the existence of this AGREEMENT. LICENSEE may also disclose the terms of the *** LICENSE and Section 5.1.2 of
this AGREEMENT to Johns Hopkins University.
	 	 	 	 	 

6

 

	

ARTICLE IX
 NOTICE
	

9.1	
 	

Any notice, request or statement hereunder shall be deemed to be sufficiently given or rendered when personally delivered, delivered by a major commercial rapid delivery courier service or mailed by certified or registered mail, return receipt
requested, and if given or rendered to LICENSEE, addressed to:
	

 	
 	

 	
 	

Genzyme Genetics

Attention: President

3400 Computer Drive

Westborough, MA 01581

USA
	

 	
 	

with a copy to:
	

 	
 	

 	
 	

Attention: General Counsel

Genzyme Corporation

500 Kendall Street

Cambridge, MA 02142

USA

7

  

	 	 	or, if given or rendered to GTG, addressed to:
	

 	
 	

 	
 	

Dr. Mervyn Jacobson

Executive Chairman

Genetic Technologies Limited

60 Hanover Street

Fitzroy, Victoria 3065

Australia
	

 	
 	

with a copy to:
	

 	
 	

 	
 	

Michael A. DeSanctis, Esq.

Faegre & Benson LLP

3200 Wells Fargo Center

1700 Lincoln Street

Denver, CO 80203

USA
	

 	
 	

or, in any case, to such changed address or person as GTG or LICENSEE shall have specified to the other by written notice.
	

ARTICLE X
 REPRESENTATIONS AND WARRANTIES
	

10.1	
 	

GTG represents and warrants that it has the full right, power, and authority to enter into and perform its obligations under this AGREEMENT and grant to LICENSEE the license and other rights as set forth herein, and there are no outstanding
agreements, grants, licenses, encumbrances, liens, or agreements, either written or implied, inconsistent therewith or pursuant to which this AGREEMENT or the parties' performance hereunder would violate, breach, or cause a default.
	

10.2	
 	

GTG represents and warrants that the execution, delivery, and performance of this AGREEMENT have been duly authorized by all necessary corporate actions on the part of GTG.
	

10.3	
 	

LICENSEE represents and warrants that it has the full right, power, and authority to enter into and perform its obligations under this AGREEMENT, and there are no outstanding agreements, grants, licenses, encumbrances, liens, or agreements, either
written or implied, inconsistent therewith or pursuant to which this AGREEMENT or the parties' performance hereunder would violate, breach, or cause a default.
	

10.4	
 	

LICENSEE represents and warrants that the execution, delivery, and performance of this AGREEMENT have been duly authorized by all necessary corporate actions on the part of LICENSEE.
	 	 	 	 	 

8

 

	

10.5	
 	

INDEMNIFICATION:
	

 	
 	

10.5.1	
 	

BY LICENSEE: LICENSEE agrees to hold GTG harmless from any claims by third parties arising from the manufacture, use, sale, importation, or other disposition of LICENSED PRODUCTS by LICENSEE. LICENSEE shall indemnify, hold harmless, and defend GTG,
and GTG's SUBSIDIARIES, affiliates, officers, directors, representatives, employees, or agents against any and all claims, causes of action, demands, judgments, settlements, expenses, or losses including, but not limited to, reasonable attorneys'
fees and court costs arising out of or in connection with: (i) the design, development, manufacture, use, sale, packaging, distribution, or shipment of LICENSED PRODUCTS; (ii) any breach by LICENSEE or LICENSEE's SUBSIDIARIES of any
representation, warranty, or covenant hereunder, or (iii) the failure of LICENSEE or LICENSEE's SUBSIDIARIES to perform any covenants or obligations contained in this AGREEMENT.
	

 	
 	

10.5.2	
 	

BY GTG: GTG shall indemnify, hold harmless, and defend LICENSEE, and LICENSEE's SUBSIDIARIES, affiliates, officers, directors, representatives, employees, or agents against any and all claims, causes of action, demands, judgments, settlements,
expenses, or losses including, but not limited to, reasonable attorneys' fees and court costs arising out of or in connection with: (i) any breach by GTG of any representation, warranty, or covenant hereunder, or (ii) the failure of GTG to
perform any covenants or obligations contained in this AGREEMENT.
	

 	
 	

10.5.3	
 	

The indemnifying party's indemnification obligations under this Section 10.5 are conditioned upon the indemnified party (i) giving prompt notice of the claim to the indemnifying party; (ii) granting sole control of the defense or
settlement of the claim or action to the indemnifying party; and (iii) providing reasonable cooperation to the indemnifying party and, at the indemnifying party's request and expense, assistance in the defense or settlement of the
claim.
	

10.6	
 	

DISCLAIMER OF WARRANTIES: EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS, TO THE EXTENT ALLOWED BY APPLICABLE LAW, ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION THE WARRANTIES OF DESIGN,
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE (EVEN IF INFORMED OF SUCH PURPOSE), NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN ALL CASES WITH RESPECT
THERETO.
	

10.7	
 	

LIMITATION OF LIABILITY: TO THE GREATEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, WITH RESPECT TO ANY CAUSE OF ACTION RELATING TO OR ARISING FROM THIS AGREEMENT (WHETHER UNDER THIS ARTICLE X OR OTHERWISE) NEITHER PARTY SHALL BE ENTITLED TO RECOVER
FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER.
	

10.8	
 	

Nothing contained in this AGREEMENT shall be construed as:
	

 	
 	

10.8.1	
 	

a warranty or representation by GTG as to the validity or scope of any LICENSED PATENT; or
	

 	
 	

10.8.2	
 	

a warranty or representation that any manufacture, sale, lease, use or other disposition hereunder will be free from infringement of patents other than those under which and to the extent to which licenses are in force hereunder; or
	 	 	 	 	 

9

 

	

 	
 	

10.8.3	
 	

a warranty or representation as to the value of the *** LICENSE set forth in Section 5.1.2 hereof; or
	

 	
 	

10.8.4	
 	

an agreement to bring or prosecute actions or suits against third parties for infringement or conferring any right to bring or prosecute actions or suits against third parties for infringement; or
	

 	
 	

10.8.5	
 	

conferring any right to use by either party, in advertising, publicity, or otherwise, any trademark, trade name or name, or any contraction, abbreviation or simulation thereof, of the other party; or
	

 	
 	

10.8.6	
 	

conferring by implication, estoppel or otherwise, upon LICENSEE, any license or other right under any intellectual property or patent, except that expressly granted hereunder.
	

ARTICLE XI
 MISCELLANEOUS
	

11.1	
 	

ENFORCEABILITY OF LICENSED PATENTS: LICENSEE agrees that it will not knowingly induce, encourage or assist any third party in connection with attacking the title or right of GTG in and to the LICENSED PATENTS or attacking the validity or
enforceability of the LICENSED PATENTS.    LICENSEE shall not be responsible for the maintenance and/or enforcement of the LICENSED PATENTS.
	

11.2	
 	

CONSTRUCTION: This AGREEMENT has been negotiated by the parties and their respective counsel. This AGREEMENT shall be interpreted fairly in accordance with its terms and without any strict construction in favor of or against either party. This
AGREEMENT shall not be construed in favor or against either party by reason of the authorship of any provisions hereof. The existence or absence of any term or condition of this AGREEMENT shall not be used in the construction or interpretation of any
other agreement between the parties. The existence or absence of any term or condition of any other agreement between the parties shall not be used in the construction or interpretation of this AGREEMENT.
	

11.3	
 	

NOTICE REGARDING INFRINGEMENT: LICENSEE shall promptly notify GTG of any third party that it reasonably believes to be infringing a LICENSED PATENT, and will use reasonable efforts to provide to GTG any non-confidential information it has in support
of such belief.
	

11.4	
 	

MODIFICATION: This AGREEMENT sets forth the entire agreement and understanding between the parties as to the subject matter of this AGREEMENT and merges all prior discussions between the parties, and no one of the parties shall be bound by any
modification of this AGREEMENT, or by any conditions, definitions, warranties, or representations with respect to the subject matter of this AGREEMENT, other than as expressly provided for herein, or as duly set forth on or subsequent to the
EFFECTIVE DATE in writing and signed by duly authorized representatives of the party to be bound thereby.
	

11.5	
 	

CHOICE OF LAW: This AGREEMENT and matters connected with the performance thereof shall be construed, interpreted, applied and governed in all respects in accordance with the laws of the State of New York (excluding conflicts of laws) and of the
United States.
	

11.6	
 	

FORUM SELECTION: The exclusive venue for any controversy or claim arising out of or in connection with this AGREEMENT shall be New York, New York and the parties hereto submit and consent to jurisdiction and venue in New York, New York, except to the
extent preempted by federal jurisdiction in which case such jurisdiction shall be in the Federal courts of New York.
	 	 	 	 	 

10

 

	

11.7	
 	

DISPUTE RESOLUTION:
	

 	
 	

11.7.1	
 	

Notwithstanding Section 11.6 above, other than injunctive relief or pre-award attachment of assets which may, but need not be, pursued in a court of law, the parties agree that, in the event of any difference, dispute or question, arising from
this AGREEMENT, the parties will endeavor to settle such matters amicably between themselves in good faith. Should the parties be unable to do so within a period of ninety (90) working days, except as provided for elsewhere herein, the matter
shall be promptly submitted to arbitration in accordance with the rules of the American Arbitration Association, and judgment upon the award rendered by the arbitrators may be entered in any court in New York having jurisdiction thereof. This
Section 11.7.1 shall not apply to any controversy or claim involving an issue of the infringement, validity, or enforceability of any patent. The arbitration shall be governed by the United States Arbitration Act, 9 U.S.C. §§ 1-16, to
the exclusion of any provisions of state law inconsistent therewith or which would produce a different result.
	

 	
 	

11.7.2	
 	

A single arbitrator who is (i) fluent in written and spoken English; and (ii) skilled and experienced in technology licensing shall be selected by agreement between the parties. If the parties fail to agree on an arbitrator, a single
arbitrator shall be selected in accordance with the procedures set forth in the Arbitration Rules of the American Arbitration Association. The arbitrator shall render a final award in accordance with the substantive law of the State of New York,
excluding the conflicts provisions of such law.
	

 	
 	

11.7.3	
 	

The arbitrator shall be fully compensated in accordance with his or her normal hourly or per diem rates for all time spent in connection with the arbitration proceeding. Pending a final award, the arbitrator's compensation and expenses shall be
advanced equally by the parties.
	

 	
 	

11.7.4	
 	

The parties may request a court for interim or provisional relief, and any such request shall not be deemed incompatible with the agreement to arbitrate or as a waiver of that agreement.
	

 	
 	

11.7.5	
 	

In no event will the arbitrator have the power to include any element of punitive damages or incidental or consequential damages in the arbitration award.
	

 	
 	

11.7.6	
 	

Notwithstanding the foregoing or anything to the contrary herein, either party may seek and obtain an injunction or other appropriate relief from a court to preserve the status quo with respect to any matter pending conclusion of the arbitration
proceeding or to enforce or protect any of its intellectual property rights.
	

11.8	
 	

EQUITABLE REMEDIES: LICENSEE acknowledges that its failure to perform any of the material terms or conditions of this AGREEMENT may result in immediate and irreparable damage to GTG. LICENSEE also acknowledges that there may be no adequate remedy at
all for such failures and that in the event thereof, GTG may be entitled to equitable relief in the nature of an injunction, pre-award attachment of assets, and/or other equitable remedies.
	

11.9	
 	

ATTORNEYS' FEES: Upon resolution of any claim or controversy arising under this AGREEMENT, the prevailing party shall be awarded its reasonable attorneys' fees and costs in addition to any other amount awarded.
	 	 	 	 	 

11

 

	

11.10	
 	

NON-DISPARAGEMENT: LICENSEE shall not make any disclosures, issue any statements or otherwise cause to be disclosed any information, statement, press release or other public disclosure, whether oral or written, which defames, slanders or libels GTG,
its shareholders, officers, directors, or employees, any aspect of the management, policies, operations, practices, or decisions of GTG, the LICENSED PATENTS, this AGREEMENT, or GTG's patent licensing activities ("STATEMENTS"). Additionally, LICENSEE
shall not knowingly permit its officers, directors or employees to issue any such STATEMENTS.
	

11.11	
 	

INDEPENDENT BUSINESS: The parties acknowledge that their business operations are completely independent and nether party shall at any time hold itself out as an agent or representative of the other party. No partnership, joint venture, or other
relationship shall be deemed to exist by virtue of this AGREEMENT or the *** LICENSE.
	

11.12	
 	

INDEPENDENT TERMS: All the terms of this AGREEMENT shall be independent and unconditional so that the performance of any one term shall not be subject to any set off or counterclaim.
	

11.13	
 	

SEVERABILITY: In the event any clause or term of this AGREEMENT is determined to be void, invalid, or unenforceable, the clause shall be reformed to the extent necessary in order to overcome the limitation and as revised this AGREEMENT shall remain
in full force and effect.
	

11.14	
 	

HEADINGS: The headings contained within this AGREEMENT are for convenience and reference purposes only. They do not form a part hereof and shall not affect the meaning or interpretation of this AGREEMENT.
	

11.15	
 	

FURTHER ASSURANCES: The parties hereto shall execute such further documents and perform such further acts as may be necessary to comply with the terms of this AGREEMENT and consummate the transactions herein provided.
	

11.16	
 	

FORCE MAJEURE: Neither party shall be held responsible if the fulfillment of any terms or provisions of this AGREEMENT are delayed or prevented by wars, revolutions, fires, floods, acts of God, acts of terrorism whether actual or threatened, or other
causes similar to those enumerated and not within the control of the party whose performance is interfered with, and which by the exercise of reasonable diligence, the party is unable to prevent.
	

11.17	
 	

COUNTERPARTS: This AGREEMENT may be executed in counterparts (and evidenced by facsimile signatures), each of which will be deemed an original and all of which together constitute one instrument.
	

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

12

 

        IN WITNESS WHEREOF, the parties hereto have caused their authorized representatives to execute this AGREEMENT. 

	GTG:	 	LICENSEE:
	
GENETIC TECHNOLOGIES LIMITED	
 	

GENZYME CORPORATION
	

By	
 	

 	
 	

By	
 	

 
	

 	
 	

 Dr. Mervyn Jacobson

Executive Chairman	
 	

 	
 	

 Henri A. Termeer

President, Chairman and Chief Executive Officer
	

 	
 	

 	
 	

By	
 	

 Michael S. Wyzga

Chief Financial Officer
	

 	
 	

 	
 	

By	
 	

 Thomas J. DesRosier

Senior Vice President, General Counsel & Chief Patent Counsel

13

 
 
 

APPENDIX "A"
  LICENSED PATENTS    
    

	APPLICATION/PATENT NUMBER
 
	 	COUNTRY
	 	STATUS

	5,192,659	 	United States	 	Granted
	5,612,179	 	United States	 	Granted
	5,789,568	 	United States	 	Granted
	E144797	 	Austria	 	Granted
	BE0414469	 	Belgium	 	Granted
	CA2023888	 	Canada	 	Granted
	DK414469	 	Denmark	 	Granted
	EP0414469	 	Europe	 	Granted
	FR0414469	 	France	 	Granted
	DE69029018	 	Germany	 	Granted
	DD299319	 	Germany	 	Granted
	GR3022410	 	Greece	 	Granted
	IL95467	 	Israel	 	Granted
	IT0414469	 	Italy	 	Granted
	JP3206812	 	Japan	 	Granted
	LI0414469	 	Liechtenstein	 	Granted
	LU0414469	 	Luxemburg	 	Granted
	NL0414469	 	Netherlands	 	Granted
	906765	 	South Africa	 	Granted
	ES2095859	 	Spain	 	Granted
	SE0414469	 	Sweden	 	Granted
	CH0414469	 	Switzerland	 	Granted
	GB0414469	 	United Kingdom	 	Granted
	5,851,762	 	United States	 	Granted
	BE0570371	 	Belgium	 	Granted
	CA2087042	 	Canada	 	Granted
	DK0570371	 	Denmark	 	Granted
	EP0570371	 	Europe	 	Granted
	FR0570371	 	France	 	Granted
	DE691316910	 	Germany	 	Granted
	IE912426	 	Ireland	 	Granted
	GR0570371	 	Greece	 	Granted
	IL98793	 	Israel	 	Granted
	IT0570371	 	Italy	 	Granted
	JP5506998	 	Japan	 	Granted
	LI0570371	 	Liechtenstein	 	Granted
	LU0570371	 	Luxemburg	 	Granted
	NL0570371	 	Netherlands	 	Granted
	915422	 	South Africa	 	Granted
	ES0570371	 	Spain	 	Granted
	SE0570371	 	Sweden	 	Granted
	CH0570371	 	Switzerland	 	Granted
	GB0570371	 	United Kingdom	 	Granted

14

QuickLinks

Exhibit 4.15

LICENSE AGREEMENT

APPENDIX "A" LICENSED PATENTS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}]]